Aronson, Stephen, Baelen, Bart Van, Kavanagh, Shane, Schwalen, Susanne

Background: Galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the Alzheimer’s type. Although several drugs are indicated for mild to moderate Alzheimer’s disease (AD), no published study has separately analysed mild and moderate AD subgroups to assess the effect of dosage.; […]

Albani, Diego, Martinelli Boneschi, Filippo, Biella, Gloria, Giacalone, Giacomo, Lupoli, Sara, Clerici, Francesca, Benussi, Luisa, Ghidoni, Roberta, Galimberti, Daniela, Squitti, Rosanna, Mariani, Stefania, Confaloni, Annamaria, Bruno, Giuseppe, Mariani, Claudio, Scarpini, Elio, Binetti, Giuliano, Magnani, Giuseppe, Franceschi, Massimo, Forloni, Gianluigi

Alzheimer’s disease (AD) is a neurodegenerative disorder often treated with donepezil, an acetylcholinesterase inhibitor. Response to donepezil is variable, probably based on patients’ genetic background in donepezil metabolizing enzymes, including cytochrome 2D6 (CYP2D6). We evaluated the association between clinical response to donepezil and a common variant (rs1080985) of CYP2D6, previously reported to be associated with […]

Aguiar, Paula, Monteiro, Larissa, Feres, Ana, Gomes, Irenio, Melo, Ailton

Objective: To determine the effects of rivastigmine patch associated with physical exercise versus rivastigmine patch alone in quality of life (QOL), cognition, activities of daily living (ADL) and functional mobility in Alzheimer’s disease (AD)subjects. Methods: A randomized, controlled, single-blinded trial was conducted in 40 patients with mild to moderate stages of AD. All patients were […]